NCT02170519View on ClinicalTrials.gov

Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide

PHASE4TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions

Pulmonary Hypertension

Interventions

DRUG

Inhaled Iloprost

A 20 mcg dose of Iloprost will be given initially.

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

lead

Duke University

OTHER

NCT02170519 - Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide | Biotech Hunter | Biotech Hunter